Amryt Pharma Share Discussion Threads

[papillon] 23/10/2021 16:21

The Hoki koki charts are, unfortunately, definitely NOT positive, richpassi. Not at the moment. Who knows what will happen to them next week?
I sold my recently acquired AMYT Shares when the Hoki koki chart went negative. Made a loss. I've put 75% of my very modest portfolio (if you can call it that) into copper explorer XTR. Already showing a modest profit. I'll tell you if I become rich, or a pauper, by Christmas. 🤣

[whatno] 23/10/2021 14:36

I think they gave an expected time but there can be no certainty. FDA has, over the last year, issued a number of rejection letters to applicants prior to the PDUFA date. These generally have said something along the lines that FDA have found issues in the submission that preclude labelling discussions. The subsequent CRL then provides details of what they didn't like - mostly, that they didn't buy the efficacy the company claimed. If Amryt does confirm that discussions have started then we can probably assume they are happy with the clinical data package at least.

[alphabravo321] 23/10/2021 14:18

They announced on last call that these discussions were starting in late Sep/Earl October I think

[whatno] 23/10/2021 14:11

Fingers crossed for approval. Amryt should confirm that they have entered into product labelling discussions with the FDA at the results announcement. I am sure that will be one of the first questions from analysts on the call if it has not been mentioned in the presentation.

[alphabravo321] 23/10/2021 12:29

Me too, stock and CVRS, the odds would have to favour approval at this late stage in my opinion

[onceaday] 23/10/2021 11:11

The price weakness is not unexpected. The biotechnology sector has generally had a terrible year - I read that the sector is down 30% vs a 30% gain for the S&P.

[waterloo01] 23/10/2021 10:59

Getting approval would be excellent, especially, like most, I hold stock and the CVR's. Good to see them out and about actively sponsoring/promoting already in the EB community

[richpassi] 23/10/2021 10:46

Im disappointed at the moment, I live in hope but won't be convinced until I see some positive Hoki koki charts from Paps ;)

[alphabravo321] 23/10/2021 10:19

PDUFA on 30th November should unlock the Priority Review Voucher. This should in turn support an increase in share price beyond 12.95 which is the trigger price for the 125 million in convertible debt. Use the proceeds from PRV to cover the 85 million for CVRS or issue new shares for CVRS and a lot could fall into place in coming weeks. This is not to mention Mycappsa, or the share price increase from PDUFA

[alphabravo321] 23/10/2021 10:02

My thoughts exactly

[bermudashorts] 23/10/2021 07:54

I guess the PDUFA date allows folk to time any potential investment here with much more precision than normal - perhaps if the build up comes it will be a little closer to the PDUFA date.

[bazworth] 23/10/2021 07:32

Not quite the build up to November that I was expecting! Hey ho!

[digadee] 20/10/2021 21:20

Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3DUBLIN, Ireland, and Boston MA, October 20, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the third quarter 2021 will be released on Wednesday, November 3, 2021 at 0700 EDT/1100 GMT.Amryt will host a conference call and webcast for analysts and investors on November 3 at 0830 EDT/1230 GMT.Webcast Player URL: https://www.globenewswire.com/Tracker?data=ljDuNvPNz3eksvQz6Jlubry0ldJ-08VvO8s9gBYdxCVduPQO9KhpKexmwHSAK-5PaF4c1F6zf8ZvVmIwDievAGNHehxia-nDSzOPRyW-EBCUOJk8ZI5lExv4Pygt_1AUotmS946C-cIkozmAarDrww== https://edge.media-server.com/mmc/p/yn6ztxz9Telephone Dial in details:United States [phone] ------------------ -------------------- United Kingdom [phone] ------------------ -------------------- Ireland [phone] ------------------ -------------------- Confirmation Code 9357809

[mcfly79] 20/10/2021 12:41

I've recently become a shareholder. The company looks very good value on a forward earnings basis. I'm still trying to get hold of the Stifel note but the consensus forecasts are shown here: hTTps://www.marketscreener.com/quote/stock/AMRYT-PHARMA-PLC-64752237/financials/ EV/EBITDA multiple of 12.5 for 2022, dropping to just 4.9 for 2023. We also have the upcoming FDA decision by 30 Nov for Oleogel. Approval should see a good increase in the share price, especially since the company believe they can obtain a priority review voucher if the drug is approved. They think they can sell this voucher for c$100m to a large pharma. The $100m extra cash would put them in a very strong cash position.

[richpassi] 18/10/2021 10:21

That's a lot of RNS's booked ;)

[bazworth] 18/10/2021 10:03

I was topping up........!!

Tee-hee

Was wondering too

[alphabravo321] 18/10/2021 09:47

What's with the multiple 1 trades

[alphabravo321] 17/10/2021 16:20

I'd imagine an RNS is due announcing Q3 results on Nov 3rd

[bermudashorts] 16/10/2021 19:56

Yep thanks - appreciated

[bazworth] 16/10/2021 18:50

Thanks delta

[bazworth] 16/10/2021 11:55

Costly reports, wonder whether they contain anything we don't already know from the various RNS releases?

[alphabravo321] 16/10/2021 08:22

httxs://www.bioworld.com/articles/512434-see-if-amryt-says-wall-street-forecasting-big-wins-for-epidermolysis-bullosa-player?v=preview

[papillon] 15/10/2021 14:35

It was the equivalent of 75p over 2 years ago. The low of 2020 was 90p back in March 2020.
Get your facts right, hotaimstocks.